Federated Hermes, Inc. Beam Therapeutics Inc. Transaction History

Federated Hermes, Inc.

  • $43.6 Billion
  • Q3 2024

A detailed history of Federated Hermes, Inc. transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Federated Hermes, Inc. holds 37,501 shares of BEAM stock, worth $948,400. This represents 0.0% of its overall portfolio holdings.

Number of Shares
37,501
Previous 20,839 79.96%
Holding current value
$948,400
Previous $488,000 88.11%
% of portfolio
0.0%
Previous 0.0%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024
BUY
$22.57 - $33.14 $376,061 - $552,178
16,662 Added 79.96%
37,501 $918,000
Q2 2024

Aug 08, 2024
BUY
$21.22 - $32.66 $442,203 - $680,601
20,839 New
20,839 $488,000
Q1 2023

May 08, 2023
BUY
$30.15 - $48.79 $301,500 - $487,900
10,000 New
10,000 $306,000
Q3 2021

Nov 15, 2021
SELL
$84.37 - $133.6 $648,974 - $1.03 Million
-7,692 Closed
0 $0
Q2 2021

Aug 16, 2021
SELL
$64.12 - $128.71 $2.93 Million - $5.88 Million
-45,696 Reduced 85.59%
7,692 $990,000
Q1 2021

May 13, 2021
SELL
$71.28 - $120.75 $3.51 Million - $5.94 Million
-49,218 Reduced 47.97%
53,388 $4.27 Million
Q4 2020

Feb 12, 2021
BUY
$22.24 - $95.63 $2.28 Million - $9.81 Million
102,606 New
102,606 $8.38 Million
Q3 2020

Nov 12, 2020
SELL
$19.0 - $30.57 $333,526 - $536,625
-17,554 Closed
0 $0
Q2 2020

Aug 13, 2020
BUY
$15.26 - $28.66 $267,874 - $503,097
17,554 New
17,554 $492,000

Others Institutions Holding BEAM

# of Institutions
236
Shares Held
75.2M
Call Options Held
438K
Put Options Held
232K
View Full List

About Beam Therapeutics Inc.

BEAM Quotes by TradingView
  • Ticker BEAM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,354,600
  • Market Cap $1.78B
  • Description
  • Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...
More about BEAM
Track This Portfolio

Track Federated Hermes, Inc. Portfolio

Follow Federated Hermes, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email